国产与原研伊马替尼一线治疗CML-CP及转换治疗的有效性与安全性比较
该回顾性研究比较了国产仿制伊马替尼(昕维)与原研伊马替尼(格列卫)一线治疗成人初诊CML-CP患者的有效性和安全性,并探索了原研药获得CCyR后转换为国产药的患者疾病稳定性和不良反应变化。结果显示两组3年CCyR、MMR、MR4.0、MR4.5累积获得率及FFS、PFS、OS率均无显著差异,不良反应发生率相似;转换组分子学反应维持或改善,不良反应可耐受。
要点
- 国产与原研伊马替尼一线治疗CML-CP的3年疗效和安全性相当。
- 人口学特征可能影响CML-CP患者TKI类型的选择。
- 原研伊马替尼获得CCyR后可安全转换为国产伊马替尼。
核心结论
- 在规范监测和管理下,国产与原研伊马替尼一线治疗CML-CP患者的有效性和安全性相当。
- 对于接受原研伊马替尼后获得稳定治疗反应的患者,可有效、安全地转换为国产伊马替尼。
研究设计与样本
- 一线治疗组:回顾性收集2013年10月至2018年8月接受国产伊马替尼(昕维)或原研伊马替尼(格列卫)一线治疗的CML-CP连续病例,共409例(国产组201例,原研组208例)。
- 转换组:回顾性收集2006年12月至2016年9月接受原研伊马替尼至少获得CCyR后转换为国产伊马替尼的CML-CP连续病例,共39例。
主要发现
- 一线治疗组中位随访25个月(范围3-62个月),国产组与原研组3年CCyR累积获得率分别为97.5%和94.5%(P=0.592)。
- 3年MMR累积获得率分别为84.3%和93.1%(P=0.208),MR4.0分别为42.7%和41.7%(P=0.277),MR4.5分别为25.4%和33.0%(P=0.306)。
- 3年FFS率分别为76.7%和81.0%(P=0.448),PFS率分别为91.8%和96.3%(P=0.325),OS率分别为95.8%和98.5%(P=0.167)。
- 多因素分析显示TKI类型不影响治疗反应及结局,两组不良反应发生率相似。
- 转换组换药后中位随访39个月(范围6-63个月),23例(58.9%)分子学反应维持原水平,12例(30.8%)分子学反应改善,新发不良反应均可耐受。
临床怎么用
- 国产与原研伊马替尼均可作为CML-CP一线治疗选择,疗效与安全性相当。
- 接受原研伊马替尼获得稳定治疗反应的患者可考虑转换为国产伊马替尼。
- 人口学特征(如教育水平、婚姻状况、户籍)可能影响TKI类型选择。
局限性
- 本研究为回顾性研究,可能存在选择偏倚。
- 一线治疗组中位随访时间较短(25个月),长期结局需进一步随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives: To compare the efficacy and safety of Chinese generic imatinib with branded imatinib as frontline therapy in adults with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) (Frontline group) , and to explore the efficacy and safety of Chinese generic imatinib in CML-CP patients switching from branded imatinib (Switching group) . Methods: Frontline group: Data of adults with newly diagnosed CML-CP receiving Chinese generic imatinib (Xinwei(®)) or branded imatinib (Glivec(®)) between October 2013 and August 2018 were retrospectively collected and analyzed. Switching group: Data of adults diagnosed with CML-CP who received branded imatinib and then switched to Chinese generic imatinib after achieving at least complete cytogenetic response (CCyR) were retrospectively collected and analyzed. Results: Frontline group: In total, 409 adult patients receiving Chinese generic imatinib (n=201) or Glivec (n=208) were included in this study. Median age was 42 years (range, 18-83 years) . Comparison of baseline showed significant difference on demographic characteristics among two cohorts: lower education level (P<0.001) , and divorced or widowed status (P=0.004) and rural household registration (P<0.001) were more common in the generic imatinib cohort than those in the Glivec cohort. There was no significant difference on age, gender, Sokal risk score, WBC and HGB between the 2 cohorts. With a median follow-up of 25 months (range, 3-62 months) , there was no significant difference on the 3-year cumulative incidence of achieving CCyR (97.5% vs 94.5%, P=0.592) , major molecular response (MMR) (84.3% vs 93.1%, P=0.208) , molecular response(4.0) (MR(4.0)) (42.7% vs 41.7%, P=0.277) , molecular response(4.5) (MR(4.5)) (25.4% vs 33.0%, P=0.306) as well as the 3-year probabilities of failure free survival (FFS) (76.7% vs 81.0%, P=0.448) , progression free survival (PFS) (91.8% vs 96.3%, P=0.325) and overall survival (OS) (95.8% vs 98.5%, P=0.167) between the generic and branded imatinib cohorts. Multivariate analysis showed the type of imatinib was not associated with treatment responses and outcomes. The incidences of adverse effects were comparable in the 2 cohorts. Switching group: In total, 39 patients switching from branded imatinib to Chinese generic imatinib after achieving at least CCyR were included in this study. Median age was 42 years (range, 23-80 years) . With a median follow-up of 39 months (range, 6-63 months) , molecular responses were maintained in 23 (58.9%) patients and improved in 12 (39.8%) patients. Adverse effects were tolerable. Conclusion: Demographic characteristics might influence the choice of the type of TKI used in CML-CP patients. There was a comparable efficacy and safety between the Chinese generic imatinib and the branded imatinib in adults with newly diagnosed CML-CP under standard management and closely monitoring. Patients could safely switch from the branded imatinib to the Chinese generic imatinib. 目的: 比较国产和原研伊马替尼一线治疗慢性髓性白血病慢性期(CML-CP)患者的有效性和安全性;探索服用原研伊马替尼获得完全细胞遗传学反应(CCyR)后转换为国产伊马替尼的患者疾病的稳定性和不良反应的变化。 方法: ①一线治疗组:回顾性收集和分析2013年10月至2018年8月期间,接受国产仿制伊马替尼(商品名昕维(®))或进口原研伊马替尼(商品名格列卫(®))作为一线治疗并定期随访、监测的CML-CP连续病例。②转换组:回顾性收集和分析2006年12月至2016年9月期间,接受原研伊马替尼至少获得CCyR后转换为国产仿制伊马替尼治疗的CML-CP连续病例。 结果: ①一线治疗组:共409例(国产伊马替尼201例,原研伊马替尼208例)患者入组,中位年龄42(18~83)岁。国产和原研组患者人口学特征差异具有统计学意义:国产伊马替尼组患者中受教育水平更低(P<0.001)、离异或丧偶者比例更高(P=0.004)、农村户籍者比例更高(P<0.001)。两组年龄、性别、Sokal危险度评分、WBC和HGB水平的差异无统计学意义。中位随访25(3~62)个月,国产伊马替尼组和原研伊马替尼组的3年CCyR、主要分子学反应(MMR)、分子学反应4.0(MR4.0)和分子学反应4.5(MR4.5)的累积获得率差异均无统计学意义(97.5%对94.5%,P=0.592;84.3%对93.1%,P=0.208;42.7%对41.7%,P=0.277;25.4%对33.0%,P=0.306),3年无失败生存(FFS)率、无进展生存(PFS)率和总生存(OS)率差异亦无统计学意义(76.7%对81.0%,P=0.448;91.8%对96.3%,P=0.325;95.8%对98.5%,P=0.167)。多因素分析显示,TKI类型不影响患者的治疗反应(CCyR、MMR、MR4.0和MR4.5累积获得率)及结局(FFS、PFS和OS)。两组不良反应发生率也相似。②转换组:共39例患者入组,中位年龄42(23~80)岁,于原研伊马替尼中位治疗38(8~114)个月后换为国产伊马替尼,换药后中位随访39(6~63)个月,23例(58.9%)患者分子学反应维持原来水平,12例(30.8%)分子学反应改善。新发药物不良反应均可耐受。 结论: 人口学特征影响CML-CP患者的用药选择。在规范的监测和管理下,国产与原研伊马替尼一线治疗CML-CP患者的有效性和安全性相当。对于接受原研伊马替尼后获得稳定治疗反应的患者,可有效、安全地转换为国产伊马替尼。.
引用
- Dou XL, Yu L, Qin YZ, et al. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31856442. doi:10.3760/cma.j.issn.0253-2727.2019.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。